Ambeed.cn

首页 / 抑制剂/激动剂 / / Trk受体 / Selitrectinib

Selitrectinib {[allProObj[0].p_purity_real_show]}

货号:A285925 同义名: LOXO-195;BAY 2731954

Selitrectinib是一种 TRK 激酶抑制剂 (TKI),对 TRKA 和 TRKC 的 IC50 值分别为 0.6 nM 和 <2.5 nM。

Selitrectinib 化学结构 CAS号:2097002-61-2
Selitrectinib 化学结构
CAS号:2097002-61-2
Selitrectinib 3D分子结构
CAS号:2097002-61-2
Selitrectinib 化学结构 CAS号:2097002-61-2
Selitrectinib 3D分子结构 CAS号:2097002-61-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Selitrectinib 纯度/质量文件 产品仅供科研

货号:A285925 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JMC, 2024. Ambeed. [ A919389 , A918471 , A995972 ]
Anal. Chem., 2024, 96(50): 19947-19954. Ambeed. [ A261947 , A1165388 ]
ACS Biomater. Sci. Eng., 2024. Ambeed. [ A220462 ]
ACS Biomater. Sci. Eng., 2024. Ambeed. [ A165235 , A110205 ]
Pharmaceutics, 2024, 16(12): 1546. Ambeed. [ A272538 , A187261 , A691302 , A506702 ]
更多 >

Selitrectinib 生物活性

描述 LOXO-195 is a new-generation and selective TRK inhibitor with IC50 values of 0.6nM, 2nM, 9.8nM, <2.5nM, 2.3nM and <2.5nM for TrkAWT, TrkAG595R, TrkAG667C, TrkCWT, TrkCG623R and TrkCG696A, respectively. Consistent with this, LOXO-195 displayed potent inhibitory effect on p-TRK in NIH-3T3 cells expressing TRK kinase acquired resistance mutations (IC50 1.6-64nM), with decrease p-ERK level (IC50 2-45nM) observed. Oral administration of LOXO-195 at dose of 30mg/kg, 100mg/kg and 300mg/kg, BID, led a dose-dependent tumor growth inhibition of mice xenograft these NIH-3T3 cells expressing different TRK resistance mutations. Distinguished from the other Trk inhibitor like larotrectinib, LOXO-195 abrogated resistance in TRK fusion–positive cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs[1].
作用机制 The specific structure of LOXO-195 with ability to accommodate the bulky, positively charged arginine side chain in the solvent front without any steric clashes distinguishes it from the other Trk inhibitor like larotrectinib.[1]

Selitrectinib 动物研究

Dose Mice: 10 mg/kg[2] (p.o.), 30 mg/kg - 300 mg/kg[3] (p.o.)
Administration p.o.
Pharmacokinetics
Animal Mice[2]
Dose 10 mg/kg
Administration p.o.
T1/2 0.82 ± 0.36 h
AUC0→4h 9754 ± 1521 ng·h/ml
Tmax 0.17 ± 0.06 h
Cmax 6623 ± 1153 ng/ml

Selitrectinib 参考文献

[1]Drilon A, Nagasubramanian R, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017 Sep;7(9):963-972.

[2]Sparidans RW, Li W, et al. Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 1;1122-1123:78-82.

[3]Drilon A, Nagasubramanian R, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017 Sep;7(9):963-972.

Selitrectinib 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.14mL

2.63mL

1.31mL

26.29mL

5.26mL

2.63mL

Selitrectinib 技术信息

CAS号2097002-61-2
分子式C20H21FN6O
分子量 380.419
别名 LOXO-195;BAY 2731954
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry,2-8°C

溶解方案

DMSO: 60 mg/mL(157.72 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。